Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age
Copyright © 2021. Published by Elsevier Inc..
OBJECTIVES: To characterize the clinical course and outcomes of children 12-18 years of age who developed probable myopericarditis after vaccination with the Pfizer-BioNTech (BNT162b2) coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccine.
STUDY DESIGN: A cross-sectional study of 25 children, aged 12-18 years, diagnosed with probable myopericarditis after COVID-19 mRNA vaccination as per the Centers for Disease Control and Prevention criteria for myopericarditis at 8 US centers between May 10, 2021, and June 20, 2021. We retrospectively collected the following data: demographics, severe acute respiratory syndrome coronavirus 2 virus detection or serologic testing, clinical manifestations, laboratory test results, imaging study results, treatment, and time to resolutions of symptoms.
RESULTS: Most (88%) cases followed the second dose of vaccine, and chest pain (100%) was the most common presenting symptom. Patients came to medical attention a median of 2 days (range, <1-20 days) after receipt of Pfizer mRNA COVID-19 vaccination. All adolescents had an elevated plasma troponin concentration. Echocardiographic abnormalities were infrequent, and 92% showed normal cardiac function at presentation. However, cardiac magnetic resonance imaging, obtained in 16 patients (64%), revealed that 15 (94%) had late gadolinium enhancement consistent with myopericarditis. Most were treated with ibuprofen or an equivalent nonsteroidal anti-inflammatory drug for symptomatic relief. One patient was given a corticosteroid orally after the initial administration of ibuprofen or an nonsteroidal anti-inflammatory drug; 2 patients also received intravenous immune globulin. Symptom resolution was observed within 7 days in all patients.
CONCLUSIONS: Our data suggest that symptoms owing to myopericarditis after the mRNA COVID-19 vaccination tend to be mild and transient. Approximately two-thirds of patients underwent cardiac magnetic resonance imaging, which revealed evidence of myocardial inflammation despite a lack of echocardiographic abnormalities.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:238 |
|---|---|
| Enthalten in: |
The Journal of pediatrics - 238(2021) vom: 30. Nov., Seite 26-32.e1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Das, Bibhuti B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 05.11.2021 Date Revised 13.12.2023 published: Print-Electronic CommentIn: J Pediatr. 2021 Nov;238:5. - PMID 34332972 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jpeds.2021.07.044 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328842419 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328842419 | ||
| 003 | DE-627 | ||
| 005 | 20231227130546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jpeds.2021.07.044 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1224.xml |
| 035 | |a (DE-627)NLM328842419 | ||
| 035 | |a (NLM)34339728 | ||
| 035 | |a (PII)S0022-3476(21)00736-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Das, Bibhuti B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.11.2021 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Pediatr. 2021 Nov;238:5. - PMID 34332972 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Inc. | ||
| 520 | |a OBJECTIVES: To characterize the clinical course and outcomes of children 12-18 years of age who developed probable myopericarditis after vaccination with the Pfizer-BioNTech (BNT162b2) coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccine | ||
| 520 | |a STUDY DESIGN: A cross-sectional study of 25 children, aged 12-18 years, diagnosed with probable myopericarditis after COVID-19 mRNA vaccination as per the Centers for Disease Control and Prevention criteria for myopericarditis at 8 US centers between May 10, 2021, and June 20, 2021. We retrospectively collected the following data: demographics, severe acute respiratory syndrome coronavirus 2 virus detection or serologic testing, clinical manifestations, laboratory test results, imaging study results, treatment, and time to resolutions of symptoms | ||
| 520 | |a RESULTS: Most (88%) cases followed the second dose of vaccine, and chest pain (100%) was the most common presenting symptom. Patients came to medical attention a median of 2 days (range, <1-20 days) after receipt of Pfizer mRNA COVID-19 vaccination. All adolescents had an elevated plasma troponin concentration. Echocardiographic abnormalities were infrequent, and 92% showed normal cardiac function at presentation. However, cardiac magnetic resonance imaging, obtained in 16 patients (64%), revealed that 15 (94%) had late gadolinium enhancement consistent with myopericarditis. Most were treated with ibuprofen or an equivalent nonsteroidal anti-inflammatory drug for symptomatic relief. One patient was given a corticosteroid orally after the initial administration of ibuprofen or an nonsteroidal anti-inflammatory drug; 2 patients also received intravenous immune globulin. Symptom resolution was observed within 7 days in all patients | ||
| 520 | |a CONCLUSIONS: Our data suggest that symptoms owing to myopericarditis after the mRNA COVID-19 vaccination tend to be mild and transient. Approximately two-thirds of patients underwent cardiac magnetic resonance imaging, which revealed evidence of myocardial inflammation despite a lack of echocardiographic abnormalities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a mRNA COVID-19 vaccine | |
| 650 | 4 | |a myocarditis | |
| 650 | 4 | |a pericarditis | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 700 | 1 | |a Kohli, Utkarsh |e verfasserin |4 aut | |
| 700 | 1 | |a Ramachandran, Preeti |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Hoang H |e verfasserin |4 aut | |
| 700 | 1 | |a Greil, Gerald |e verfasserin |4 aut | |
| 700 | 1 | |a Hussain, Tarique |e verfasserin |4 aut | |
| 700 | 1 | |a Tandon, Animesh |e verfasserin |4 aut | |
| 700 | 1 | |a Kane, Colin |e verfasserin |4 aut | |
| 700 | 1 | |a Avula, Sravani |e verfasserin |4 aut | |
| 700 | 1 | |a Duru, Chioma |e verfasserin |4 aut | |
| 700 | 1 | |a Hede, Sannya |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Kavita |e verfasserin |4 aut | |
| 700 | 1 | |a Chowdhury, Devyani |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Mercer, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudhuri, Nita Ray |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Bhavi |e verfasserin |4 aut | |
| 700 | 1 | |a Ang, Jocelyn Y |e verfasserin |4 aut | |
| 700 | 1 | |a Asmar, Basim |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez, Joselito |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Danyal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of pediatrics |d 1945 |g 238(2021) vom: 30. Nov., Seite 26-32.e1 |w (DE-627)NLM000019003 |x 1097-6833 |7 nnns |
| 773 | 1 | 8 | |g volume:238 |g year:2021 |g day:30 |g month:11 |g pages:26-32.e1 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jpeds.2021.07.044 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 238 |j 2021 |b 30 |c 11 |h 26-32.e1 | ||